Experts in diabetes and endocrinology at Riley Children’s Health deliver specialized care for infants, children and adolescents with diabetes and other endocrine disorders. Our board certified physicians have completed additional subspecialty training in pediatric endocrinology and pediatric diabetology. Ten certified diabetes and education specialists provide a wide range of resources and support to patients and their families. DIABETES AND ENDOCRINOLOGY
RESEARCH HIGHLIGHTS
Our program is enrolling in more than 30 diabetes and endocrine-related clinical and observational studies, including: ■ Leading study site for novel glucagon formulations, including inhaled and soluble liquid glucagon ■ Research study site for breakthrough therapy teplizumab; the first FDA-approved prevention treatment for Type 1 diabetes ■ Studies of novel growth hormone formulations for children with short stature; new therapies for children with precocious puberty; and studies to improve bone health in children with rare bone diseases ■ Studies investigating connections between the microbiome and beta cell stress and the development and progression of Type 1 diabetes Specialized programs ■ Comprehensive Care Center for Congenital Adrenal Hyperplasia ■ Endocrine Diseases Newborn Screening Program ■ Type 1 Diabetes Program (including early-stage Type 1 diabetes) ■ Type 2 Diabetes Program ■ Youth Diabetes Prevention Program The diabetes program at Riley Children’s is accredited by the Association of Diabetes Care and Education Specialists. ■ Prader-Willi Syndrome Program ■ Metabolic Bone Disease Program ■ Muscular Dystrophy Program ■ Gender Health Program ■ Disorders of Sex Development Program ■ Turner Syndrome Program ■ Late Endocrine Effects of Cancer Therapy Program ■ Telehealth Endocrine and Diabetes Program
DIVISION CHIEF Linda A. DiMeglio, MD, MPH Professor of Pediatrics, IU School of Medicine > Connect with Dr. DiMeglio on Doximity. >
Program distinctions
■ Ranked among the top 15 pediatric diabetes and endocrinology programs in the nation by U.S. News & World Report ■ Only comprehensive care center in the Midwest for congenital adrenal hyperplasia
17 board certified physicians
>
See full team member list
Leading-edge technologies More than 50% of our Type 1 diabetes patients are using advanced technologies: ■ Continuous glucose monitors ■ Insulin pumps ■ Hybrid closed-loop insulin delivery systems Our endocrinologists are pioneering research focused on improving the use of these latest technologies in people with diabetes, including utilization of these systems in very young children and those with newly diagnosed diabetes.
■ Active in clinical and translational research studies for diabetes and endocrine disorders
NOTABLE PUBLICATIONS
55 research publications in 2022
Diabetologia: January 2022 HOMA2-B Enhances Assessment of Type 1 Diabetes Risk Among TrialNet Pathway to Prevention Participants Diabetes Spectrum: March 2022 COVID-19 Pandemic Effects on Caregivers of Youth with Type 1 Diabetes: Stress and Self-Efficacy Hormone Research in Paediatrics: June 2022 Do All Patients with Congenital Adrenal Hyperplasia Need to Be on Hydrocortisone Three Times a Day in Order to Have Normal Growth?
Clinical Pediatrics: February 2022 Pediatric Type 2 Diabetes Presentation During the COVID-19 Pandemic The Journal of Clinical Endocrinology and Metabolism: September 2022 The Variability of Growth and Puberty in Growth Hormone-Treated Children Born Small for Gestational Age Diabetes Care: December 2022 Persistence of ß-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children with Marked Metabolic Impairment at Screening
Refer a patient online
Annual Report 2022 – 2023
317.944.3889
Made with FlippingBook. PDF to flipbook with ease